During the past 10 years, neoadjuvant chemotherapy has taken its rightful place in the treatment of breast cancer (BC). Clinical studies have shown that women who have achieved a complete pathologic tumor regression (pCR), are characterized by a significant improvement in survival compared with those who have not achieved such marked regression. A meta-analysis carried out on the instructions of FDA (Food and Drug Administration), has shown that the achievement of a complete pathologic response (pCR) as an intermediate marker of survival benefit, seen mainly in women with aggressive breast cancer subtypes: triple negative and HER2-positive breast cancer. In patients with HER2 + breast cancer, addition of trastuzumab to neoadjuvant chemotherapy doubles the frequency of pCR and correlates with increased survival.